AZD 2811

Drug Profile

AZD 2811

Alternative Names: AZD 1152 hQPA; AZD2811

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AstraZeneca; BIND Therapeutics
  • Developer AstraZeneca; Pfizer
  • Class Acetamides; Antineoplastics; Fluorobenzenes; Pyrazoles; Quinazolines
  • Mechanism of Action Aurora kinase B inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Solid tumours
  • Preclinical Diffuse large B cell lymphoma; Lung cancer

Most Recent Events

  • 13 Jul 2017 AstraZeneca plans a phase I/II trial for Acute myeloid leukaemia (Second-line therapy or greater, Treatment-naive) and Myelodysplastic syndromes (Second-line therapy or greater, Treatment-naive) (IV) (NCT03217838)
  • 01 Apr 2017 Pharmacodynamics data from preclinical studies in Cancer presented at the 108th Annual Meeting of the American Association of Cancer (AACR-2017)
  • 02 May 2016 BIND Therapeutics files for Chapter 11 bankruptcy
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top